The Latest Breaking News on Pharma

Councillors from all parties have agreed there must be more work done on helping people into recovery to cut the number of drug-related deaths.

North American drug developers have signed a deal with a British company to trial the therapeutic benefits of psychedelic medicines in London.

New York (AFP) - US biopharmaceutical firm Amgen said Monday it has reached agreement to acquire Horizon Therapeutics, which specializes in medicine for rare and auto-immune diseases, for $27.8 billion.

In Britain we’re used to getting what we want, when we want – but the supply issues that have emptied shelves are here to stay, says Guardian columnist Gaby Hinsliff

Scientists heaped scorn on Twitter owner Elon Musk after he suggested Sunday that Dr. Anthony Fauci, the nation’s top infectious disease expert, deserved to be prosecuted — while belittling the inclusive use of pronouns, to boot.

Horizon Therapeutics, whose U.S. headquarters is in Deerfield, is a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases.

Pharma company Bristol-Myers Squibb (BMY) is working on strengthening its pipeline and has raised its annual dividend recently. Hence, the stock might be a solid addition to your portfolio this month. Read on….

Amgen announced a $28.3 billion plan to acquire Horizon Therapeutics on Monday, leading HZNP stock to soar higher.

Six floor office building on New Oxford Street will be workplace for 3,000 staff including CEO

A number of chemists have reported difficulties obtaining amoxicillin and penicillin as concern over infection grows

Pharma company Rigel’s (RIGL) REZLIDHIA recently achieved the U.S. Food and Drug Administration’s approval for treating relapsed or refractory acute myeloid leukemia, helping the stock to soar. RIGL shares have gained more than 30% over the past month. Given the industry tailwinds, RIGL might be the ideal stock to buy…